Login Register Cart 0
Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

The Residual Risks Associated with Atherothrombosis of Recurrent Ischemic Stroke (IS) After Non-cardiogenic IS

Author(s): Hengshu Chen and Fafa Tian*

Volume 20, Issue 1, 2023

Published on: 27 January, 2023

Page: [149 - 161] Pages: 13

DOI: 10.2174/1567202620666221222114325

Price: $65

Abstract

Recurrent ischemic stroke (IS) is one of the leading causes of disability and death worldwide. Patients with recurrent IS, in comparison with survivors of the initial non-cardiogenic IS, have more serious neurological deficit and longer hospital stay with heavier family and socio-economic burden. Therefore, recurrent IS is a major challenge that we urgently need to address. The recurrence rate of non-cardiogenic IS is not zero and even shows an increasing trend over a long period of time, despite receiving evidence-based management in accordance with guideline, indicating that patients suffering from non-cardiogenic IS and who are receiving optimal management remain at considerable residual risks (RRs) responsible for the recurrence of cerebrovascular events. In addition to low-density lipoprotein cholesterol (LDL-C) and platelets, some new non-traditional parameters such as high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], peripheral circulating platelet-derived microvesicles, white blood cells-platelet complexes, NODlike receptor protein 3 (NLRP3) inflammasome, monomeric C-reactive protein, neutrophils and their products (neutrophil extracellular traps, NETs), may also be potential sources of RRs for recurrent IS. On the basis of the three pillars of secondary stroke prevention, namely, blood pressure reduction, lipid-lowering and antiplatelet therapy, the reduction in RRs may provide additional protection against recurrent IS. With this background, the identification and quantification of RRs associated with disease heterogeneity and individualized treatment strategies based on risk stratification are favorable in the mitigation of the huge stroke burden people unceasingly face.

« Previous Next »
[1]
Arsava EM, Kim GM, Oliveira-Filho J, et al. Prediction of early recurrence after acute ischemic stroke. JAMA Neurol 2016; 73(4): 396-401.
[http://dx.doi.org/10.1001/jamaneurol.2015.4949] [PMID: 26926383]
[2]
He Q, Wu C, Guo W, et al. Hospital-based study of the frequency and risk factors of stroke recurrence in two years in china. J Stroke Cerebrovasc Dis 2017; 26(11): 2494-500.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.05.026] [PMID: 28939046]
[3]
Aarnio K, Haapaniemi E, Melkas S, Kaste M, Tatlisumak T, Putaala J. Long-term mortality after first-ever and recurrent stroke in young adults. Stroke 2014; 45(9): 2670-6.
[http://dx.doi.org/10.1161/STROKEAHA.114.005648] [PMID: 25061076]
[4]
Pan Y, Li Z, Li J, et al. Residual risk and its risk factors for ischemic stroke with adherence to guideline-based secondary stroke prevention. J Stroke 2021; 23(1): 51-60.
[http://dx.doi.org/10.5853/jos.2020.03391] [PMID: 33600702]
[5]
Lin B, Zhang Z, Mei Y, et al. Cumulative risk of stroke recurrence over the last 10 years: a systematic review and meta-analysis. Neurol Sci 2021; 42(1): 61-71.
[http://dx.doi.org/10.1007/s10072-020-04797-5] [PMID: 33040195]
[6]
Xu J, Mo J, Zhang X, et al. Nontraditional risk factors for residual recurrence risk in patients with ischemic stroke of different etiologies. Cerebrovasc Dis 2022; 51(5): 630-8.
[http://dx.doi.org/10.1159/000523919] [PMID: 35390802]
[7]
Li J, Li Z, Lyu T, Cheng S, Pu Y, Wang Y. Residual recurrence risk of ischemic cerebrovascular events: Elements and implications. Neurosci Bull 2021; 37(9): 1361-4.
[http://dx.doi.org/10.1007/s12264-021-00733-5] [PMID: 34164776]
[8]
Pepine CJ. Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Ann Med 2010; 42(1): 19-35.
[http://dx.doi.org/10.3109/07853890903260898] [PMID: 20092398]
[9]
Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17(7): 796-808.
[http://dx.doi.org/10.1038/nm.2399] [PMID: 21738161]
[10]
Sirimarco G, Labreuche J, Bruckert E, et al. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 2014; 45(5): 1429-36.
[http://dx.doi.org/10.1161/STROKEAHA.113.004229] [PMID: 24736236]
[11]
Park JH, Ovbiagele B. Optimal combination secondary prevention drug treatment and stroke outcomes. Neurology 2015; 84(1): 50-6.
[http://dx.doi.org/10.1212/WNL.0000000000001099] [PMID: 25411440]
[12]
Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113(3): 485-90.
[http://dx.doi.org/10.1016/j.amjcard.2013.10.035] [PMID: 24315113]
[13]
M’barek L, Sakka S, Megdiche F, et al. Traditional risk factors and combined genetic markers of recurrent ischemic stroke in adults. J Thromb Haemost 2021; 19(10): 2596-604.
[http://dx.doi.org/10.1111/jth.15448] [PMID: 34241942]
[14]
Hoshino T, Uchiyama S, Wong LKS, et al. Differences in characteristics and outcomes between asian and non-asian patients in the tiaregistry. Stroke 2017; 48(7): 1779-87.
[http://dx.doi.org/10.1161/STROKEAHA.117.016874] [PMID: 28584002]
[15]
Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis 2016; 245: 161-70.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.12.018] [PMID: 26722833]
[16]
Guedeney P, Claessen BE, Kalkman DN, et al. Residual inflammatory risk in patients with low ldl cholesterol levels undergoing percutaneous coronary intervention. J Am Coll Cardiol 2019; 73(19): 2401-9.
[http://dx.doi.org/10.1016/j.jacc.2019.01.077] [PMID: 31097159]
[17]
Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and cholesterol risk in the fourier trial. Circulation 2018; 138(2): 131-40.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034032] [PMID: 29530884]
[18]
Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep 2020; 22(11): 66.
[http://dx.doi.org/10.1007/s11883-020-00883-3] [PMID: 32880743]
[19]
Barfejani AH, Jafarvand M, Seyedsaadat SM, Rasekhi RT. Donepezil in the treatment of ischemic stroke: Review and future perspective. Life Sci 2020; 263: 118575.
[http://dx.doi.org/10.1016/j.lfs.2020.118575] [PMID: 33058916]
[20]
Kumral E, Evyapan D, Gökçay F, Karaman B, Orman M. Association of baseline dyslipidemia with stroke recurrence within five-years after ischemic stroke. Int J Stroke 2014; 9(SA100) (Suppl. A100): 119-26.
[http://dx.doi.org/10.1111/ijs.12341] [PMID: 25088494]
[21]
Zhao L, Wang R, Song B, et al. Association between atherogenic dyslipidemia and recurrent stroke risk in patients with different subtypes of ischemic stroke. Int J Stroke 2015; 10(5): 752-8.
[http://dx.doi.org/10.1111/ijs.12471] [PMID: 25924059]
[22]
Lindenstrøm E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ 1994; 309(6946): 11-5.
[http://dx.doi.org/10.1136/bmj.309.6946.11] [PMID: 8044059]
[23]
Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45(7): 2160-236.
[http://dx.doi.org/10.1161/STR.0000000000000024] [PMID: 24788967]
[24]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014] [PMID: 31591002]
[25]
Kim JS. Role of blood lipid levels and lipid-lowering therapy in stroke patients with different levels of cerebral artery diseases: Reconsidering recent stroke guidelines. J Stroke 2021; 23(2): 149-61.
[http://dx.doi.org/10.5853/jos.2021.01249] [PMID: 34102752]
[26]
Sirimarco G, Deplanque D, Lavallée PC, et al. Atherogenic dyslipidemia in patients with transient ischemic attack. Stroke 2011; 42(8): 2131-7.
[http://dx.doi.org/10.1161/STROKEAHA.110.609727] [PMID: 21737806]
[27]
Hoshino T, Ishizuka K, Toi S, et al. Atherogenic dyslipidemia and residual vascular risk after stroke or transient ischemic attack. Stroke 2022; 53(1): 79-86.
[http://dx.doi.org/10.1161/STROKEAHA.121.034593] [PMID: 34470483]
[28]
Sanossian N, Saver JL, Navab M, Ovbiagele B. High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke 2007; 38(3): 1104-9.
[http://dx.doi.org/10.1161/01.STR.0000258347.19449.0f] [PMID: 17255541]
[29]
Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the atherogenic dyslipidemia complex: The next frontier in cvd prevention beyond lowering LDL cholesterol. Diabetes 2016; 65(7): 1767-78.
[http://dx.doi.org/10.2337/db16-0046] [PMID: 27329952]
[30]
Fruchart JC, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential. Cardiovasc Diabetol 2019; 18(1): 71.
[http://dx.doi.org/10.1186/s12933-019-0864-7] [PMID: 31164165]
[31]
Hoshino T, Ishizuka K, Toi S, Seki M, Kitagawa K. Effects of pemafibrate in patients with stroke and hypertriglyceridemia: Baseline cerebral artery diseases and 3-month laboratory outcomes. J Atheroscler Thromb 2022; 29(7): 1020-30.
[http://dx.doi.org/10.5551/jat.63036] [PMID: 34248089]
[32]
Palacio-Portilla EJ, Roquer J, Amaro S, et al. Dyslipidemias and stroke prevention: Recommendations of the study group of cerebrovascular diseases of the spanish society of neurology. Neurología 2022; 37(1): 61-72.
[http://dx.doi.org/10.1016/j.nrleng.2020.07.021] [PMID: 35074190]
[33]
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the american heart association/american stroke association. Stroke 2021; 52(7): e364-467.
[http://dx.doi.org/10.1161/STR.0000000000000375] [PMID: 34024117]
[34]
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26): 2518-28.
[http://dx.doi.org/10.1056/NEJMoa0902604] [PMID: 20032323]
[35]
Lange KS, Nave AH, Liman TG, Grittner U, Endres M, Ebinger M. Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke. Stroke 2017; 48(1): 36-42.
[http://dx.doi.org/10.1161/STROKEAHA.116.014436] [PMID: 27856951]
[36]
Arnold M, Schweizer J, Nakas CT, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J 2021; 42(22): 2186-96.
[http://dx.doi.org/10.1093/eurheartj/ehab081] [PMID: 33709115]
[37]
Tsimikas S, Fazio S, Ferdinand KC, et al. Nhlbi working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018; 71(2): 177-92.
[http://dx.doi.org/10.1016/j.jacc.2017.11.014] [PMID: 29325642]
[38]
Després AA, Perrot N, Poulin A, et al. Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18f-sodium fluoride positron emission tomography and computed tomography. CJC Open 2019; 1(3): 131-40.
[http://dx.doi.org/10.1016/j.cjco.2019.03.004] [PMID: 32159096]
[39]
Hovingh GK, Kastelein JJP, van Deventer SJH, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2015; 386(9992): 452-60.
[http://dx.doi.org/10.1016/S0140-6736(15)60158-1] [PMID: 26047975]
[40]
Sahebkar A, Reiner Ž, Simental-Mendía LE, Ferretti G, Cicero AFG. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism 2016; 65(11): 1664-78.
[http://dx.doi.org/10.1016/j.metabol.2016.08.007] [PMID: 27733255]
[41]
Ying Q, Chan DC, Pang J, Marcovina SM, Barrett PHR, Watts GF. PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin‐treated patients with very high apolipoprotein(a) concentration. J Intern Med 2022; 291(6): 870-6.
[http://dx.doi.org/10.1111/joim.13457] [PMID: 35112754]
[42]
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020; 382(3): 244-55.
[http://dx.doi.org/10.1056/NEJMoa1905239] [PMID: 31893580]
[43]
Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med 2022; 28(1): 96-103.
[http://dx.doi.org/10.1038/s41591-021-01634-w] [PMID: 35027752]
[44]
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019; 13(3): 374-92.
[http://dx.doi.org/10.1016/j.jacl.2019.04.010] [PMID: 31147269]
[45]
Tsimikas S. Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. Eur Heart J 2021; 42(22): 2197-200.
[http://dx.doi.org/10.1093/eurheartj/ehab251] [PMID: 34000000]
[46]
Kohn B, Ashraf AP, Wilson DP. Should lipoprotein(a) be measured in youth? J Pediatr 2021; 228: 285-9.
[http://dx.doi.org/10.1016/j.jpeds.2020.08.042] [PMID: 32822740]
[47]
Nurmohamed NS, Kaiser Y, Schuitema PCE, et al. Finding very high lipoprotein(a): The need for routine assessment. Eur J Prev Cardiol 2022; 29(5): 769-76.
[PMID: 34632502]
[48]
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020; 41(24): 2275-84.
[http://dx.doi.org/10.1093/eurheartj/ehz310] [PMID: 31111151]
[49]
Chen KN, He L, Zhong LM, Ran YQ, Liu Y. Meta-analysis of dyslipidemia management for the prevention of ischemic stroke recurrence in china. Front Neurol 2020; 11: 483570.
[http://dx.doi.org/10.3389/fneur.2020.483570] [PMID: 33329292]
[50]
Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18(33): 5197-214.
[http://dx.doi.org/10.2174/138161212803251899] [PMID: 22724408]
[51]
Olie RH, van der Meijden PEJ, ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost 2018; 2(2): 188-98.
[http://dx.doi.org/10.1002/rth2.12080] [PMID: 30046721]
[52]
Chen Z, Sandercock P, Pan H, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31(6): 1240-9.
[http://dx.doi.org/10.1161/01.STR.31.6.1240] [PMID: 10835439]
[53]
Paciaroni M, Ince B, Hu B, et al. Benefits and risks of clopidogrel vs. Aspirin monotherapy after recent ischemic stroke: A systematic review and meta-analysis. Cardiovasc Ther 2019; 2019: 1-12.
[http://dx.doi.org/10.1155/2019/1607181] [PMID: 31867054]
[54]
Narasimhalu K, Ang YK, Tan DSY, De Silva DA, Tan KB. Cost effectiveness of genotype-guided antiplatelet therapy in asian ischemic stroke patients: Ticagrelor as an alternative to clopidogrel in patients with cyp2c19 loss of function mutations. Clin Drug Investig 2020; 40(11): 1063-70.
[http://dx.doi.org/10.1007/s40261-020-00970-y] [PMID: 32959334]
[55]
Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9(10): 959-68.
[http://dx.doi.org/10.1016/S1474-4422(10)70198-8] [PMID: 20833591]
[56]
Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367(9523): 1665-73.
[http://dx.doi.org/10.1016/S0140-6736(06)68734-5] [PMID: 16714187]
[57]
Zhu X, Cao G. Safety of glycoprotein iib-iiia inhibitors used in stroke-related treatment: A systematic review and meta-analysis. Clin Appl Thromb Hemost 2020; 26: 1076029620942594.
[http://dx.doi.org/10.1177/1076029620942594] [PMID: 32727211]
[58]
Brown DL, Levine DA, Albright K, et al. Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: A systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2021; 52(7): e468-79.
[http://dx.doi.org/10.1161/STR.0000000000000377] [PMID: 34024115]
[59]
Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369(1): 11-9.
[http://dx.doi.org/10.1056/NEJMoa1215340] [PMID: 23803136]
[60]
Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med 2018; 379(3): 215-25.
[http://dx.doi.org/10.1056/NEJMoa1800410] [PMID: 29766750]
[61]
Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or tia. N Engl J Med 2020; 383(3): 207-17.
[http://dx.doi.org/10.1056/NEJMoa1916870] [PMID: 32668111]
[62]
Toyoda K, Uchiyama S, Yamaguchi T, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 2019; 18(6): 539-48.
[http://dx.doi.org/10.1016/S1474-4422(19)30148-6] [PMID: 31122494]
[63]
Wong KSL, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9(5): 489-97.
[http://dx.doi.org/10.1016/S1474-4422(10)70060-0] [PMID: 20335070]
[64]
Liu L, Chen W, Zhou H, et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol 2020; 5(2): 159-76.
[http://dx.doi.org/10.1136/svn-2020-000378] [PMID: 32561535]
[65]
European stroke organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk tia. Eur Stroke J 2021; 6(2): CXCL.
[66]
Park HK, Ko SB, Jung KH, et al. 2022 update of the korean clinical practice guidelines for stroke: Antithrombotic therapy for patients with acute ischemic stroke or transient ischemic attack. J Stroke 2022; 24(1): 166-75.
[http://dx.doi.org/10.5853/jos.2021.02628] [PMID: 35135073]
[67]
Turan TN, Zaidat OO, Gronseth GS, et al. Stroke prevention in symptomatic large artery intracranial atherosclerosis practice advisory: Report of the aan guideline subcommittee. Neurology 2022; 98(12): 486-98.
[http://dx.doi.org/10.1212/WNL.0000000000200030] [PMID: 35314513]
[68]
Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: A population-base cohort study. Stroke 2020; 51(8): 2435-44.
[http://dx.doi.org/10.1161/STROKEAHA.120.028992] [PMID: 32646337]
[69]
Rubenstein DA, Yin W. Platelet-activation mechanisms and vascular remodeling. Compr Physiol 2018; 8(3): 1117-56.
[http://dx.doi.org/10.1002/cphy.c170049] [PMID: 29978900]
[70]
Tobin WO, Kinsella JA, Collins DR, et al. Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: First results from the TRinity AntiPlatelet responsiveness (TrAP) study. Br J Haematol 2011; 152(5): 640-7.
[http://dx.doi.org/10.1111/j.1365-2141.2010.08539.x] [PMID: 21223254]
[71]
Ikeda Y, Yamanouchi J, Kumon Y, Yasukawa M, Hato T. Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. Thromb Res 2018; 172: 14-20.
[http://dx.doi.org/10.1016/j.thromres.2018.10.003] [PMID: 30342278]
[72]
Wiśniewski A, Filipska K, Sikora J, Kozera G. Aspirin resistance affects medium-term recurrent vascular events after cerebrovascular incidents: A three-year follow-up study. Brain Sci 2020; 10(3): 179.
[http://dx.doi.org/10.3390/brainsci10030179] [PMID: 32204465]
[73]
Wiśniewski A, Filipska K. The phenomenon of clopidogrel high on-treatment platelet reactivity in ischemic stroke subjects: A comprehensive review. Int J Mol Sci 2020; 21(17): 6408.
[http://dx.doi.org/10.3390/ijms21176408] [PMID: 32899176]
[74]
Anderson R, Theron AJ, Steel HC, Nel JG, Tintinger GR. Adp-mediated upregulation of expression of cd62p on human platelets is critically dependent on co-activation of p2y1 and p2y12 receptors. Pharmaceuticals (Basel) 2020; 13(12): 420.
[http://dx.doi.org/10.3390/ph13120420] [PMID: 33255391]
[75]
Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: A systematic review and meta-analysis. Circulation 2017; 135(1): 21-33.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024913] [PMID: 27806998]
[76]
Yi X, Han Z, Zhou Q, Cheng W, Lin J, Wang C. Concomitant use of proton-pump inhibitors and clopidogrel increases the risk of adverse outcomes in patients with ischemic stroke carrying reduced-function cyp2c19*2. Clin Appl Thromb Hemost 2018; 24(1): 55-62.
[http://dx.doi.org/10.1177/1076029616669787] [PMID: 27637911]
[77]
Schrick D, Molnár T, Tőkés-Füzesi M, Molnár A, Ezer E. Circulating microvesicles in convalescent ischemic stroke patients: A contributor to high-on-treatment residual platelet reactivity? Front Biosci-Land 2022; 27(5): 158.
[http://dx.doi.org/10.31083/j.fbl2705158] [PMID: 35638425]
[78]
Hoshino H, Toyoda K, Omae K, et al. Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: Subanalysis of the CSPS.Com trial. Stroke 2021; 52(11): 3430-9.
[http://dx.doi.org/10.1161/STROKEAHA.121.034378] [PMID: 34404237]
[79]
Toyoda K, Omae K, Hoshino H, et al. Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: A CSPS.Com trial post hoc analysis. Neurology 2022; 98(10): e983-92.
[http://dx.doi.org/10.1212/WNL.0000000000200064] [PMID: 35074890]
[80]
Miyamoto S, Ogasawara K, Kuroda S, et al. Japan stroke society guideline 2021 for the treatment of stroke. Int J Stroke 2022; 17(9): 1039-49.
[http://dx.doi.org/10.1177/17474930221090347] [PMID: 35443847]
[81]
Kovacevic KD, Greisenegger S, Langer A, et al. The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. Sci Rep 2021; 11(1): 3092.
[http://dx.doi.org/10.1038/s41598-021-82747-7] [PMID: 33542410]
[82]
Wang Y, Johnston C, Bath PM, et al. Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial. Stroke Vasc Neurol 2021; 6(2): 280-5.
[http://dx.doi.org/10.1136/svn-2020-000791] [PMID: 33952670]
[83]
Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010; 105(12): 2533-49.
[http://dx.doi.org/10.1038/ajg.2010.445] [PMID: 21131924]
[84]
Jeridi D, Pellat A, Ginestet C, et al. The safety of long-term proton pump inhibitor use on cardiovascular health: A meta-analysis. J Clin Med 2022; 11(14): 4096.
[http://dx.doi.org/10.3390/jcm11144096] [PMID: 35887860]
[85]
Levine GN, Bates ER, Bittl JA, et al. 2016 acc/aha guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol 2016; 68(10): 1082-115.
[http://dx.doi.org/10.1016/j.jacc.2016.03.513] [PMID: 27036918]
[86]
Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: Guideline recommendations from the international consensus group. Ann Intern Med 2019; 171(11): 805-22.
[http://dx.doi.org/10.7326/M19-1795] [PMID: 31634917]
[87]
Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021; 85: 1-13.
[http://dx.doi.org/10.1016/j.ejim.2020.11.014] [PMID: 33279389]
[88]
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 2018; 53(1): 34-78.
[http://dx.doi.org/10.1093/ejcts/ezx334] [PMID: 29045581]
[89]
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Kardiol Pol 2017; 75(12): 1217-99.
[http://dx.doi.org/10.5603/KP.2017.0224] [PMID: 29251754]
[90]
Ibánez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 2017; 70(12): 1082.
[http://dx.doi.org/10.1016/j.rec.2017.11.010] [PMID: 29198432]
[91]
Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34(23): 1708-3.
[http://dx.doi.org/10.1093/eurheartj/eht042]
[92]
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016; 14(1): 179.
[http://dx.doi.org/10.1186/s12916-016-0718-z] [PMID: 27825371]
[93]
Biswas M, Rahaman S, Biswas TK, Ibrahim B. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis. Int J Clin Pharm 2021; 43(5): 1360-9.
[http://dx.doi.org/10.1007/s11096-021-01261-y] [PMID: 33774763]
[94]
Kafian S, Mobarrez F, Wallén H, Samad B. Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets 2015; 26(5): 467-73.
[http://dx.doi.org/10.3109/09537104.2014.940304] [PMID: 25025694]
[95]
Ezer E, Schrick D, Tőkés-Füzesi M, Szapary L, Bogar L, Molnar T. A novel approach of platelet function test for prediction of attenuated response to clopidogrel. Clin Hemorheol Microcirc 2019; 73(2): 359-69.
[http://dx.doi.org/10.3233/CH-190580] [PMID: 31156147]
[96]
Schrick D, Ezer E, Tokes-Fuzesi M, Szapary L, Molnar T. Novel predictors of future vascular events in post-stroke patients-a pilot study. Front Neurol 2021; 12: 666994.
[http://dx.doi.org/10.3389/fneur.2021.666994] [PMID: 34220675]
[97]
Ishikawa T, Shimizu M, Kohara S, Takizawa S, Kitagawa Y, Takagi S. Appearance of WBC-platelet complex in acute ischemic stroke, predominantly in atherothrombotic infarction. J Atheroscler Thromb 2012; 19(5): 494-501.
[http://dx.doi.org/10.5551/jat.10637] [PMID: 22659534]
[98]
Lim ST, Murphy SJX, Murphy SM, et al. Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. J Neurol Sci 2022; 441: 120334.
[http://dx.doi.org/10.1016/j.jns.2022.120334] [PMID: 36030623]
[99]
Molnar T, Csecsei P. Prevention of non-cardiogenic ischemic stroke: Towards personalized stroke care. In: Dehkharghani S, Ed. Stroke. Brisbane (AU): Exon Publications 1995.
[100]
Everett BM. Residual inflammatory risk: A common and important risk factor for recurrent cardiovascular events. J Am Coll Cardiol 2019; 73(19): 2410-2.
[http://dx.doi.org/10.1016/j.jacc.2019.02.056] [PMID: 31097160]
[101]
Yagita Y. Cholesterol and inflammation in stroke recurrence. J Atheroscler Thromb 2019; 26(5): 406-7.
[http://dx.doi.org/10.5551/jat.ED107] [PMID: 30568078]
[102]
Nagornev VA. Current aspects of pathogenesis of atherosclerosis. Arkh Patol 1991; 53(9): 13-22.
[PMID: 1772356]
[103]
Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis. J Am Coll Cardiol 2009; 54(23): 2129-38.
[http://dx.doi.org/10.1016/j.jacc.2009.09.009] [PMID: 19942084]
[104]
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473(7347): 317-25.
[http://dx.doi.org/10.1038/nature10146] [PMID: 21593864]
[105]
Hansson GK. Inflammation and atherosclerosis. Circulation 2017; 136(20): 1875-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030484] [PMID: 28916641]
[106]
Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016; 37(22): 1720-2.
[http://dx.doi.org/10.1093/eurheartj/ehw024] [PMID: 26908943]
[107]
Ridker PM, MacFadyen JG, Thuren T, Libby P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J 2020; 41(23): 2153-63.
[http://dx.doi.org/10.1093/eurheartj/ehz542] [PMID: 31504417]
[108]
Alkhalil M. Mechanistic insights to target atherosclerosis residual risk. Curr Probl Cardiol 2021; 46(3): 100432.
[http://dx.doi.org/10.1016/j.cpcardiol.2019.06.004] [PMID: 31285037]
[109]
Li J, Pan Y, Xu J, et al. Residual inflammatory risk predicts poor prognosis in acute ischemic stroke or transient ischemic attack patients. Stroke 2021; 52(9): 2827-36.
[http://dx.doi.org/10.1161/STROKEAHA.120.033152] [PMID: 34281380]
[110]
Ridker PM. How common is residual inflammatory risk? Circ Res 2017; 120(4): 617-9.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.310527] [PMID: 28209792]
[111]
Kelly PJ, Camps-Renom P, Giannotti N, et al. Carotid plaque inflammation imaged by (18)f-fluorodeoxyglucose positron emission tomography and risk of early recurrent stroke. Stroke 2019; 50(7): 1766-73.
[http://dx.doi.org/10.1161/STROKEAHA.119.025422] [PMID: 31167623]
[112]
McCabe JJ, O’Reilly E, Coveney S, et al. Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis. Eur Stroke J 2021; 6(1): 62-71.
[http://dx.doi.org/10.1177/2396987320984003] [PMID: 33817336]
[113]
Libby P. Inflammation in atherosclerosis-no longer a theory. Clin Chem 2021; 67(1): 131-42.
[http://dx.doi.org/10.1093/clinchem/hvaa275] [PMID: 33393629]
[114]
Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013; 14(8): 812-20.
[http://dx.doi.org/10.1038/ni.2639] [PMID: 23812099]
[115]
Karasawa T, Takahashi M. The crystal-induced activation of NLRP3 inflammasomes in atherosclerosis. Inflamm Regen 2017; 37(1): 18.
[http://dx.doi.org/10.1186/s41232-017-0050-9] [PMID: 29259717]
[116]
Zheng L, Xu H, Zheng F, et al. Intervention time decides the status of autophagy, NLRP3 activity and apoptosis in macrophages induced by ox‐LDL. Lipids Health Dis 2022; 21(1): 107.
[http://dx.doi.org/10.1186/s12944-022-01714-x] [PMID: 36284323]
[117]
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119-31.
[http://dx.doi.org/10.1056/NEJMoa1707914] [PMID: 28845751]
[118]
Segal HC, Burgess AI, Poole DL, Mehta Z, Silver LE, Rothwell PM. Population-based study of blood biomarkers in prediction of subacute recurrent stroke. Stroke 2014; 45(10): 2912-7.
[http://dx.doi.org/10.1161/STROKEAHA.114.005592] [PMID: 25158774]
[119]
Li J, Zhao X, Meng X, et al. High-sensitive c-reactive protein predicts recurrent stroke and poor functional outcome: Subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke 2016; 47(8): 2025-30.
[http://dx.doi.org/10.1161/STROKEAHA.116.012901] [PMID: 27328699]
[120]
Kitagawa K, Hosomi N, Nagai Y, et al. Cumulative effects of ldl cholesterol and crp levels on recurrent stroke and tia. J Atheroscler Thromb 2019; 26(5): 432-41.
[http://dx.doi.org/10.5551/jat.45989] [PMID: 30318492]
[121]
Biondi-Zoccai G, Garmendia CM, Abbate A, et al. Atherothrombosis prevention and treatment with anti-interleukin-1 agents. Curr Atheroscler Rep 2020; 22(1): 4.
[http://dx.doi.org/10.1007/s11883-020-0819-1] [PMID: 31932973]
[122]
Li Y, Zhang Y, Lu J, Yin Y, Xie J, Xu B. Anti‐inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. J Cell Mol Med 2021; 25(17): 8087-94.
[http://dx.doi.org/10.1111/jcmm.16798] [PMID: 34312998]
[123]
Tapoi L, Benchea L, Siriopol D, Kanbay M, Covic A. Colchicine use in acute coronary syndromes: An update. Angiology 2021; 72(6): 503-10.
[http://dx.doi.org/10.1177/0003319720985644] [PMID: 33412929]
[124]
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381(26): 2497-505.
[http://dx.doi.org/10.1056/NEJMoa1912388] [PMID: 31733140]
[125]
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; 383(19): 1838-47.
[http://dx.doi.org/10.1056/NEJMoa2021372] [PMID: 32865380]
[126]
Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380(8): 752-62.
[http://dx.doi.org/10.1056/NEJMoa1809798] [PMID: 30415610]
[127]
Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009; 105(2): 128-37.
[http://dx.doi.org/10.1161/CIRCRESAHA.108.190611] [PMID: 19520972]
[128]
Coveney S, McCabe JJ, Murphy S, O’Donnell M, Kelly PJ. Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2020; 5(5): CD012825.
[PMID: 32392374]
[129]
Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: A new target for prevention. Stroke 2021; 52(8): 2697-706.
[http://dx.doi.org/10.1161/STROKEAHA.121.034388] [PMID: 34162215]
[130]
Kelly P, Weimar C, Lemmens R, et al. Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial. Eur Stroke J 2021; 6(2): 222-8.
[http://dx.doi.org/10.1177/2396987320972566] [PMID: 34414298]
[131]
Moschonas IC, Tselepis AD. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis 2019; 288: 9-16.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.06.919] [PMID: 31280097]
[132]
Chen R, Zhang X, Gu L, et al. New insight into neutrophils: A potential therapeutic target for cerebral ischemia. Front Immunol 2021; 12: 692061.
[http://dx.doi.org/10.3389/fimmu.2021.692061] [PMID: 34335600]
[133]
Kim BJ, Cho YJ, Hong KS, et al. Treatment intensification for elevated blood pressure and risk of recurrent stroke. J Am Heart Assoc 2021; 10(7): e019457.
[http://dx.doi.org/10.1161/JAHA.120.019457] [PMID: 33787300]
[134]
Guo Y, Zhang Y, Zhao J, et al. Impact of diabetes on platelet function in acute ischemic stroke patients taking dual antiplatelet therapy. Front Neurol 2021; 12: 712024.
[http://dx.doi.org/10.3389/fneur.2021.712024] [PMID: 34803869]
[135]
Zhang J, Gong Y, Zhao Y, Jiang N, Wang J, Yin X. Post-stroke medication adherence and persistence rates: a meta-analysis of observational studies. J Neurol 2021; 268(6): 2090-8.
[http://dx.doi.org/10.1007/s00415-019-09660-y] [PMID: 31792672]
[136]
Lin B, Zhang Z, Guo Y, et al. Perceptions of recurrence risk and behavioural changes among first‐ever and recurrent stroke survivors: A qualitative analysis. Health Expect 2021; 24(6): 1962-70.
[http://dx.doi.org/10.1111/hex.13335] [PMID: 34363288]
[137]
Widjaja KK, Chulavatnatol S, Suansanae T, et al. Knowledge of stroke and medication adherence among patients with recurrent stroke or transient ischemic attack in Indonesia: a multi-center, cross-sectional study. Int J Clin Pharm 2021; 43(3): 666-72.
[http://dx.doi.org/10.1007/s11096-020-01178-y] [PMID: 33124676]
[138]
Chapman B, Bogle V. Adherence to medication and self-management in stroke patients. Br J Nurs 2014; 23(3): 158-66.
[http://dx.doi.org/10.12968/bjon.2014.23.3.158] [PMID: 24526023]
[139]
Shani SD, Varma RP, Sarma PS, Sylaja PN, Kutty VR. Life style and behavioural factors are associated with stroke recurrence among survivors of first episode of stroke: A case control study. J Stroke Cerebrovasc Dis 2021; 30(4): 105606.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2021.105606] [PMID: 33548808]
[140]
Kelly PJ, Albers GW, Chatzikonstantinou A, et al. Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies. Lancet Neurol 2016; 15(12): 1238-47.
[http://dx.doi.org/10.1016/S1474-4422(16)30236-8] [PMID: 27751555]
[141]
Yang D, Liu J, Yao W, et al. The MRI enhancement ratio and plaque steepness may be more accurate for predicting recurrent ischemic cerebrovascular events in patients with intracranial atherosclerosis. Eur Radiol 2022; 32(10): 7004-13.
[http://dx.doi.org/10.1007/s00330-022-08893-2] [PMID: 35771249]
[142]
Sun YV, Hu YJ. Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. Adv Genet 2016; 93: 147-90.
[http://dx.doi.org/10.1016/bs.adgen.2015.11.004] [PMID: 26915271]
[143]
Carbone F, Montecucco F, Xu S, Banach M, Jamialahmadi T, Sahebkar A. Epigenetics in atherosclerosis: key features and therapeutic implications. Expert Opin Ther Targets 2020; 24(8): 719-21.
[http://dx.doi.org/10.1080/14728222.2020.1764535] [PMID: 32354276]
[144]
Refaat A, Yap ML, Pietersz G, et al. In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications. J Nanobiotechnology 2022; 20(1): 450.
[http://dx.doi.org/10.1186/s12951-022-01648-7] [PMID: 36243718]
[145]
Gil-Núñez A, Masjuan J, Montaner J, et al. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance. Neurología (English Edition) 2022; 37(2): 136-50.
[http://dx.doi.org/10.1016/j.nrleng.2020.11.014] [PMID: 34906541]
[146]
Sagris D, Ntaios G, Georgiopoulos G, et al. Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. Int J Stroke 2021; 16(6): 738-50.
[http://dx.doi.org/10.1177/1747493020971970] [PMID: 33202196]
[147]
Bruckert E, Kereiakes DJ, Koren MJ, et al. PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. J Clin Lipidol 2019; 13(3): 443-54.
[http://dx.doi.org/10.1016/j.jacl.2019.04.005] [PMID: 31076261]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy